Personalized vaccines comprise of patient derived DCs which are engineered and amplified and injected back to host circulation have shown promising tumor suppressing effect [144] Fig. 2J. Similarly, delivery of ligand for toll-like receptor 3 (TLR3) or STING agonist to activate DCs at the site of tumor are showing promising result in enhancing DC based immune response [145]. This evidence concerns the gene TLR3 and neoplasm.